Clinical trials: Anticoagulation, open to volunteers
Ischemic Stroke, Atrial Fibrillation
Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation
Background Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting up to 10% of the elderly. Ischemic stroke is the main complication of AF and cardioembolism is one of the leading causes of ischemic stroke…
- Conditions
- Ischemic Stroke, Atrial Fibrillation, Cerebrovascular Disorders, Brain Diseases
- Trial name
- CARE-AF (NCT06954610)
- Testing
- No intervention
- Where
- Switzerland
- Volunteers
- 500 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
ECMO
PACE: Prostacyclin AntiCoagulation in ECMO
Extracorporeal membrane oxygenation (ECMO) is a machine that temporarily supports the heart and/or lungs and is a critical rescue therapy for refractory cardiac and respiratory failure in pediatric populations.
- Trial name
- PACE (NCT07837869)
- Testing
- Dose-escalation study of epoprostenol as adjunct anticoagulation in ECMO
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Garrett Keim
Prophylactic, Anticoagulation
Prophylactic Anticoagulation for Central Venous Line Insertion in Critically Ill Children
This will be a Prospective, randomized, open- label, parallel-group, center trial, which will include 80 of Children which will be admitted at Pediatric Intensive Care Unit (PICU) of Menoufia university Hospital from August 2026…
- Trial name
- NCT07710482
- Testing
- Enoxaparin
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Menoufia University
Atrial Fibrillation Patients With Moderate or High Stroke Risk Who Had Undergone Catheter Ablation of Atrial Fibrillation
AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study)
There has no evidence for the anticoagulation in patients who had undergone catheter ablation of atrial fibrillation, and has maintained sinus rhythm for more than 1 year.
- Trial name
- NCT04432220
- Testing
- Anticoagulation group(Apixaban group)
- Where
- South Korea
- Volunteers
- 840 people
- Sponsor
- Yonsei University
Atrial Fibrillation (AF)
Discontinuation of Anticoagulation With Intensive Rhythm Monitoring in Post-ablation Patients With Atrial Fibrillation
DIAMOND-AF is a multicenter, randomized, open-label trial evaluating whether discontinuing oral anticoagulation after successful atrial fibrillation ablation can reduce bleeding risk without increasing death or thromboembolism…
- Trial name
- DIAMOND-AF (NCT06871228)
- Testing
- NOAC discontinuation, NOAC continuation, Smartwatch single-lead ECG monitoring
- Where
- 22 sites in China
- Volunteers
- 4,100 people
- Sponsor
- Beijing Anzhen Hospital
Extracorporeal Membrane Oxygenation Complication
Anticoagulation-free VV ECMO for Acute Respiratory Failure
Currently international experts recommend therapeutic anticoagulation for veno-venous extracorporeal membrane oxygenation (VV-ECMO).
- Trial name
- A-FREE ECMO (NCT04273607)
- Testing
- Subcutaneous Heparin
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Damian Ratano
PRP
PRP Yield and Platelet Distribution With EDTA
We will test and compare the platelet distribution after centrifugation and the platelet yield of ACD-A and EDTA anticoagulated blood
- Trial name
- NCT07084272
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Harrison, Theodore, M.D.
Hemodialysis Access Failure, Kidney Disease, End-Stage
Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dysfunction (APICATH-HD)
This randomized, single-center, PROBE trial evaluates whether adding low-dose apixaban (2.5 mg orally every 12 hours) to standard intraluminal heparin lock prolongs primary functional patency of tunneled hemodialysis catheters…
- Conditions
- Hemodialysis Access Failure, Kidney Disease, End-Stage, Hemodialysis Catheter
- Trial name
- APICATH-HD (NCT07404345)
- Testing
- Apixaban, Heparin sodium lock solution
- Where
- Mexico
- Volunteers
- 54 people
- Sponsor
- Hospital Civil de Guadalajara
Behcet Disease, Behcet Disease and Vascular Involvement
Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease
This study is a Phase III, multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial investigating the treatment of lower extremity venous thrombosis associated with Behçet's Disease.
- Conditions
- Behcet Disease, Behcet Disease and Vascular Involvement, Deep Venous Thromboses, Post Thrombotic Syndrome
- Trial name
- BETTER (NCT06925698)
- Testing
- Rivaroxaban plus immunosupression
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 110 people
- Sponsor
- Marmara University
Thrombosis, Cancer
Safety of Perioperative Anticoagulation Management in People With Active Cancer Undergoing Cancer-Related Surgery or Procedures (ACE-HIGH Study)
The purpose of this study is to help find how safe current practices are when managing blood thinners in people with cancer who are having surgery or medical procedures.
- Conditions
- Thrombosis, Cancer, Thrombosis, Deep Vein, Atrial Fibrillation (AF)
- Trial name
- ACE-HIGH (NCT07372716)
- Testing
- standardized perioperative anticoagulation management Guideline
- Where
- Canada
- Volunteers
- 700 people
- Sponsor
- Ottawa Hospital Research Institute
Ischemic Stroke, Atrial Fibrillation
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
Atrial fibrillation (AF) is one of the most common cardiac arrhythmias and cardioembolic stroke due to AF is its major complication. Direct oral anticoagulants (DOAC) reduce the risk of cardioembolism in patients with AF.
- Trial name
- ELAPSE (NCT05976685)
- Testing
- Left atrial appendage Occlusion, DOAC
- Where
- 33 sites in Belgium, Germany and 4 more
- Volunteers
- 482 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Atrial Fibrillation, Stroke
Computerized Decision Support to Prevent Stroke in Atrial Fibrillation
Atrial fibrillation (AF) is the most preventable cause of stroke. However, despite widely available risk stratification tools, numerous options for oral anticoagulation, and evidence-based practice guidelines, anticoagulation for…
- Trial name
- AF-ALERT3 (NCT06355986)
- Testing
- Alert-based computerized decision support
- Where
- 2 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- Brigham and Women's Hospital
Atrial Fibrillation (AF)
Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual)
The purpose of the PAUSE-Virtual Study is to show that by changing pre-surgery visits with patients taking a blood thinner (direct oral anticoagulant (apixaban, dabigatran, edoxaban, rivaroxaban or warfarin) when the participant…
- Trial name
- PAUSEVirtual (NCT06844227)
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 1,780 people
- Sponsor
- McMaster University
Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke)
The Southern-Norway Post-Stroke Atrial Fibrillation Study
This study evaluates whether a procedure using a new wireless heart sensor patch is equal to or better than the standard hospital procedures and equipment at detecting an irregular heartbeat called Atrial Fibrillation (AF) after…
- Conditions
- Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke), Ischemic Stroke, Secondary Prevention
- Trial name
- SNAPS (NCT07407790)
- Testing
- Patch ECG, Standard Care (in control arm)
- Where
- Norway
- Volunteers
- 450 people
- Sponsor
- Sorlandet Hospital HF
Cancer, VTE (Venous Thromboembolism)
DOAC - Dosing Options in AntiCoagulation Prophylaxis
Blood clots, also known as venous thromboembolism (VTE), are a common and serious complication for people with cancer. They can lead to pain, hospitalizations, delayed cancer treatment, and even death.
- Trial name
- DOAC (NCT07005024)
- Testing
- Apixaban 2.5 mg twice daily, Apixaban 5 mg once daily, No anticoagulation
- Where
- United States
- Volunteers
- 996 people
- Sponsor
- University of Vermont
Aortic Valve Disease
DIrect Oral Anticoagulation and Bioprothesis Aortic Valve
DIAMOND study is a national, multicentre, randomized, parallel-group, open label study in patients (aged ≥18 years) with aortic bioprosthesis (excluding TAVI) at least 7 days after cardiac surgery.
- Trial name
- DIAMOND (NCT05687448)
- Testing
- Apixaban 5 MG Oral Tablet, Aspirin 75 to 100mg once a day
- Where
- France
- Volunteers
- 1,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Male Infertility, Heart Valve Disease
Warfarin Effects on Male Fertility After Cardiac Surgery
Young male patients undergoing cardiac surgery may require oral anticoagulation with warfarin either lifelong, such as after mechanical valve replacement, or for a limited postoperative period, for example following valve repair…
- Trial name
- NCT07330869
- Testing
- Semen analysis, sperm DNA fragmentation and hormonal evaluation
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Città di Lecce Hospital, GVM Care & Research
Coagulation Disorder
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
The aim of this study is to find out the effects of TAK-330 compared with four-factor prothrombin complex concentrate (4F-PCC) as part of standard treatment other than Prothromplex Total for anticoagulation reversal in…
- Trial name
- NCT05156983
- Testing
- TAK-330, SOC 4F-PCC
- Where
- 64 sites in United States, Argentina and 13 more
- Volunteers
- 440 people
- Sponsor
- Takeda
Left Atrial Appendage Closure
Oral Anticoagulation Versus Left Atrial Appendage Occlusion Added to Direct Oral Anticoagulation in Patients with Stroke Despite Oral
A total of 380 patients with ischemic stroke despite OAC will be included. Patients will be randomized 1:1 to the best medical treatment (control) or the combination of LAAO and DOAC or OAC.
- Trial name
- ADDLAAO (NCT06869811)
- Testing
- LAA Closurse
- Where
- Spain
- Volunteers
- 380 people
- Sponsor
- Hospital Clinic of Barcelona
Atrial Fibrillation, Coronary Artery Disease
Antithrombotic Strategy for AF Patients With High Risk CAD
Anticoagulation therapy is recommended for patients with atrial fibrillation (AF) in order to prevent ischemic stroke and systemic embolism.
- Trial name
- ADAPT AFFIRM (NCT06866665)
- Testing
- Anticoagulation Monotherapy, Combination therapy
- Volunteers
- 1,400 people
- Sponsor
- Yonsei University